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Osteoblastic lesionsmirrors the complexity seen in patients would be invaluable for pre-clinical testing of novel
treatments. The microstructural changes in the femurs of mice implanted with PCSD1, a
new patient-derived xenograft from a surgical prostate cancer bone metastasis specimen,
were determined.
Methods: Quantitative micro-computed tomography (micro-CT) and histological analyses were
performed to evaluate the effects of direct injection of PCSD1 cells or media alone (Control)
into the right femurs of Rag2/gc/ male mice.
Results: Bone lesions formed only in femurs of mice injected with PCSD1 cells. Bone volume
(BV) was significantly decreased at the proximal and distal ends of the femurs (p < 0.01)
whereas BV (p < 0.05) and bone shaft diameter (p < 0.01) were significantly increased along
the femur shaft.
Conclusion: PCSD1 cells reproducibly induced bone loss leading to osteolytic lesions at the
ends of the femur, and, in contrast, induced aberrant bone formation leading to osteoblastic
lesions along the femur shaft. Therefore, the interaction of PCSD1 cells with different bone
region-specific microenvironments specified the type of bone lesion. Our approach can be used
to determine if different bone regions support more therapy resistant tumor growth, thus,
requiring novel treatments.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is the most common solid cancer in men
and the second leading cause of cancer of death in men [1].
The majority of prostate cancer patients with metastatic
disease will develop bone metastases. Patients with bone
metastases are at risk of skeletal related events, including
spinal cord compression, pathological fracture, and severe
bone pain leading to surgery and/or radiation to alleviate
bone pain, and prevent or repair pathologic fractures. In a
recent large US study, 10% of prostate cancer patients with
newly diagnosed bone metastasis already had skeletal
related events (SREs) [2]. During follow-up, the cumulative
incidence of SREs in these patients increased: 21.5% at 6
months, 30.4% at 12 months, 41.9% at 24 months, and 48.9%
at 36 months [2]. Therefore, bone metastases contribute
substantially to patients’ mortality and morbidity.
Bone metastases in most men with prostate cancer are a
mix of osteoblastic and osteolytic lesions [3]. The mecha-
nisms by which prostate cancer tumor cells induce osteo-
blastic lesions which are characterized by new bone
formation, or osteolytic lesions which are characterized by
increased bone resorption leading to thinning bone are
unclear. It is hypothesized that osteoblastic lesions are
formed by intense osteoblastic activity, preceded by oste-
oclastic bone resorption in patients with prostate cancer
[3]. However, it is possible that prostate tumor cells can
induce metastatic bone lesions that do not involve osteo-
clastic activity [4]. The relative contribution of extrinsic
factors from specific bone microenvironments versus fac-
tors intrinsic to the tumor cells themselves to the type of
bone lesion formed is not understood. The reciprocal
interaction of the tumor cells and bone microenvironment
also gives rise to a pathologically altered tumor microen-
vironment which can drive further malignant tumor pro-
gression [5].
The type of cancer cells themselves plays a crucial role
in determining the type of bone reaction both in patients
and mouse models transplanted with human tumor cells.Most of the group of cancers that often metastasize to bone
such as breast, lung and kidney cancer invariably induce
osteolytic lesions [2,4]. Prostate cancer, on the other hand,
has a higher proportion of osteoblastic and mixed lesions
compared to purely osteolytic lesions [1e5]. The
complexity of the types of osseous lesions induced by bone
metastatic prostate cancer in patients was comprehen-
sively analyzed in the recent work of Vargas and co-workers
in which the types of bone metastatic lesions in castration
resistant prostate cancer patients were evaluated using
computed tomography (CT), FDG-PET and FDHT-PET [6].
They showed a range of at least six bone lesion types
classified along a spectrum from dense osteoblastic to
mixed osteoblastic-osteolytic to purely osteolytic in nature
even within a single patient. Patients with the highest
number of bone lesions and whose lesions had the highest
18F-DHT (dihydrotestosterone, DHT) uptake had the short-
est overall survival [6]. Different types of osseous lesions
were also investigated in the study of bone metastasis
samples obtained in a rapid autopsy study from patients
who had died of metastatic castrate resistant disease
[7e9]. Histomorphometric analysis revealed significant
heterogeneity comprising a wide range of osteolytic to
osteoblastic osseous responses within individual patients
[8]. The mechanisms and clinical implications of the types
of prostate cancer bone metastasis lesions found even
within an individual patient need to be determined. Eluci-
dating the mechanisms underlying bone metastatic lesion
formation may lead to the development of new treatments
for bone metastatic prostate cancer [10].
The complexity of prostate cancer bone lesions makes
them extremely challenging to study and, therefore, to
develop effective treatments in patients [6,10]. Thus,
there is a significant need for accurate models to investi-
gate prostate cancer interaction with the bone microenvi-
ronment. In experimental models of cancer bone
metastasis, prostate cancer cells or xenografts harvested
from human rapid autopsy programs show differential
osteoblastic versus osteolytic reactions in the mouse
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patient-derived xenograft series produced a range of intra-
tibial bone reactions depending on the line [9]. The LNCaP
derived cell line, C4-2-B which formed mixed osteoblastic
and osteolytic lesions in mouse bone xenografts, was
derived from an original lymph node metastasis of a patient
[5,11]. Intra-tibial xenograft transplantation of the PC3
prostate adenocarcinoma cancer cell line derived from a
patient bone marrow metastasis formed purely osteolytic
lesions, while LAPC9 cells which were derived from a pa-
tient femoral bone metastasis, formed purely osteoblastic
lesions [12e15]. Prostate cancer xenografts designated as
MDA models, showed some of the lines are osteoblastic and
others are osteolytic in which fibroblast growth factor 9
(FGF9) played a mediating role [16].
Pre-clinical studies with these models have led to sig-
nificant advances in patient treatments, however, they
were not always predictive of patient responses in larger
clinical trials such as for the drug, cabozantinib [17,18].
This has been attributed to species-specific differences in
mouse and human bone microenvironments, as well as the
extensive passaging of some of these cell lines during
which they have acquired documented changes from the
original tumor specimen. However, prostate cancer is
often highly heterogeneous within and between patients,
therefore, a greater diversity and range of patient-derived
xenograft (PDX) models representing more patients need
to be available to test new therapies. For these reasons,
we undertook the development of new PDXs of prostate
cancer bone metastasis. We developed PCSD1, a new intra-
femoral xenograft model of prostate cancer bone metas-
tasis derived from a surgical bone metastasis specimen
from the femur of a patient with a pathologic fracture
[19]. Preliminary micro-computed tomography (micro-CT)
analysis revealed that PCSD1 cells induced mixed osteo-
blastic and osteolytic bone lesions when transplanted into
femurs of immunodeficient male mice which closely
resembled the bone lesions in the patient [19]. In the
current study, we quantitatively defined the microstruc-
tural changes in the murine femurs into which PCSD1 were
injected using high-resolution two- (2D) and three-
dimensional (3D) micro-CT.
2. Materials and methods
2.1. Patient derived xenograft tumor cells
All studies with human samples were performed with the
approval of the University of California, San Diego (UCSD),
School of Medicine Institutional Review Board. The patient
provided written informed consent. Prostate cancer bone
metastasis cells were obtained directly from the bone
metastatic lesion in the proximal femur of a patient with
castrate-resistant prostate cancer having a hemi-
arthroplasty to treat a pathologic fracture in the right
femur head. Gleason score of original tumor was 10 (5 þ 5),
and mixed osteoblastic and osteolytic lesions were
observed in the proximal femur on CT. Tumor cells used to
create the xenograft were directly derived from the orig-
inal specimen or only early tumor passages and prepared
according to the protocols in Raheem et al. [19].2.2. Direct intra-femoral injection in mice
All animal protocols were approved by the UCSD animal
welfare IACUC committee. Male, 6e8week old Rag2/gc/
mice were used for direct intra-femoral injection [19]. Mice
were anesthetized with intra-peritoneal (i.p.) injection of a
mix of 100 mg/kg ketamine and 10 mg/kg Xylazine. The right
knee was held in flexed position and a 25-gauge needle
(Monoject 200 25  5/8A) was inserted into the femoral
condyle until there was no resistance. It was used as a port-
hole for injection of 15 mL sample using a 0.3 mL syringe and
27-gauge needle. Sample injection was performed slowly
with minimal resistance. Leg was immediately straightened
after injection and held straight for approximately 1 min and
antibiotic ointment applied. Mice were injected with atipa-
mezole (Antisedan, Zoetis, Pasippany, New Jersey, USA) and
placed on a warm DeltaPhase pad (Braintree Scientific,
Braintree, MA, USA) and carefully observed until full
recovery.
2.3. Micro-CT: image acquisition, processing and
analysis
For quantitative micro-CT analysis 13 mice injected intra-
femorally (i.f.) with PCSD1 cells plus Matrigel in which the
injection site needle hole was visible through the condyle in
micro-CT imaging and macroscopic tumor formation were
selected for the PCSD1 group and eightmice injected i.f. with
Media/Matrigel alone, with needle hole in the condyle were
selected for the Control group. Mice were sacrificed 8e10
weeks after injection. Inferior limbswere carefully harvested
from all mice, and fixed in 10% neutral buffered formalin.
Femurs were scanned on a SkyScan 1076 micro-CT scanner
(Bruker, Kontich, Belgium), and regions of interest (ROIs)
were determined using established guidelines [20]. Parame-
ters analyzed by micro-CT included total cross-sectional tis-
sue area (Tt.Ar), cortical bone area (Ct.Ar), cortical area
fraction (Ct.Ar/Tt.Ar), cortical thickness (Ct.Th), tissue
mineral density (TMD), tissue volume, bone surface (BS),
bone volume (BV), trabecular thickness (Tb.Th), trabecular
spacing (Tb.Sp), trabecular number (Tb.N), structure model
index (SMI), and bone mineral density (BMD), bone mineral
content (BMC), and tissuemineral content (TMC) [20]. Femurs
were imaged and acquired using the micro-CT SkyScan 1076
(Bruker, Kontich, Belgium) at a source power of 59 kV/167 mA
and spatial resolution of 9.06 mm/pixel with 0.5 mm-thick
aluminumfilter. The rotationwas set at 0.7 per step for 180.
Samples were set into 50mL centrifuge tube and packed with
saline wettened gauze to prevent hydration and movement
during scanning.
2.4. Image processing
The reconstructions were performed with NRecon software
package (SkyScan) to obtain transaxial grayscale images
[21]. Each ROI was delineated so as to include both sides of
the whole femur. 2D transaxial, coronal, and sagittal
images were obtained with Data Viewer software
(SkyScan) based on the ROI data [21]. The longitudinal
axis along the femur (on the coronal and sagittal images)
was set parallel to the bone shaft, and transaxial images
232 T. Hirata et al.along this axis were used to create 3D images or to analyze
bone quantity [21]. The longitudinal axis was determined
by two independent researchers (TH and TY). Micro-CT
visualization of the needle hole through the growth plate at
the condyle was used as confirmation of successful intra-
femoral injection on the 2D and 3D images.
2.5. Micro-CT 3D imaging
To create 3D micro-CT-based femur models, the 2D trans-
axial images were imported in the 3D reconstruction of
each femur using the 3D reconstruction software package
Mimics 14.12 (Materialise NV, Plymouth, MI, USA). Femur
length was measured on the 3D image from the top of
greater trochanter to the top of the medial condyle. The
maximum diameter of the bone shaft was also measured on
the 3D image. Measurement of femur length and maximum
femur diameter was performed by two independent re-
searchers (TH and TY).
2.6. 2D radiographic image analysis for bone
quantification
The parameters for bone quantity were analyzed in the
whole femur bone, the condyle area, the middle of the
bone shaft (cortical bone area), the proximal bone area and
trabecular bone. The whole femur bone length was
measured from the top of the medial condyle to the
bifurcation of the femur neck at the top of greater
trochanter. Different bone regions expressed as percentage
of this total length to take into account the variation in
femur lengths between mice. The condyle region was
measured from the top of the condyle to the growth plate.
Cortical bone area was measured from the midpoint of the
total femur length. The cortical bone area for each sample
was proportionally adjusted, or normalized, to the relative
longitudinal value as a percentage of the length of the
longest femur as detailed in Supplemental fig. 1. The
proximal bone area of each femur head was measured from
the bifurcation of the femur neck which was defined as the
end of proximal area and normalized as percentage of the
longest femur as detailed in Supplemental fig. 1. The
trabecular bone area of the femur was measured from the
growth plate, an important landmark for trabecular area,
and extending proximally 10.92% of total femur length
(Supplemental fig. 1).
2.7. Bone quantity analysis
All parameters for bone quantity analysis were calculated
automatically with CT-Analyzer software. Bone threshold
values were determined by the Otsu method [22] in Skyscan
CT-Analyzer Software (Bruker, Kartuizersweg 3B, 2550
Kontich, Belgium). In condyle and proximal bone analysis,
total bone volume was defined as the outer surface
outline as described in Bouxsein guidelines [20] and in
Supplemental fig. 2A. In cortical bone analysis, total bone
volume was defined as external cortical surface and outside
edge of endocortical surface (Supplemental fig. 2B). BV is
defined as the volume of the region segmented as bone
while total volume (TV) is the volume of the entire region ofinterest including soft tissue and the space inside the bone.
The TV measurement software/algorithm approximates the
irregular surface and small porosity as smooth surface. TV
of condyle, proximal bone, and cortical bone was deter-
mined with an automated “Shrink wrap” method (21,
Supplemental fig. 2). TV of trabecular bone was defined as
irregular and anatomic region of interest drawn manually a
few voxels away from the endocortical surface [21] as
shown in Supplemental fig. 2. Bone volume per total volume
(BV/TV), bone surface density (BS/TV), open porosity
(Po(op)), total porosity (Po(tot)), mean Tb.Th, mean Tb.N,
mean Tb.Sp, trabecular pattern factor (Tb.Pf), SMI were
computed using a marching-cubes algorithm and calculated
on 3D image [20,21]. Cross-sectional BV and cross-sectional
thickness (Cs.Th) were calculated on 2D images.
2.8. Statistical analysis
The results of bone quantity parameters were expressed as
the mean  SD. The student’s t-test, Welch’s test, and
ManneWhitney’s U test were used to determine significant
differences between two independent groups. The stu-
dent’s t-test was used under the condition that both groups
had normal distributions and equal variances. Welch’s test
was used under the condition that both groups had normal
distributions but non-equal variances. ManneWhitney’s test
was used when each group had non-normal distribution.
Normal distributions were confirmed with ShapiroeWilk W
test, and equal variances were confirmed with F test. One-
way analysis of variance (ANOVA) was used for comparison
among three individual groups. All tests were considered
significant when p < 0.05. All statistical analysis was per-
formed with JMP 10 (SAS Institute Inc., Cary, NC, USA).
2.9. Histology
After micro-CT scanning, the left and right legs which were
already fixed in 10% formalin prior to micro-CT scanning
were decalcified with 10% EDTA then embedded in optimum
cutting temperature compound (OCT, Tissue-Plus, Fisher
Scientific, USA) and frozen in isopentane/dry ice bath for
cryosections or paraffin embedded as described in Raheem
et al. [19]. Sagittal plane 5 mm sections were stained with
hematoxylin and eosin (H&E). To examine the histological
structure as well as the distribution and content of pro-
teoglycan, multichromatic FAST staining was also used
which comprised Alcian blue, safranin O, tartrazine, and
fast green dyes was performed as previously described [23].
Images were captured using the Aperio ScanScope (Leica
Biosystems, Buffalo Grove, IL, USA) and Keyence digital
microscopes (Itasca, IL, USA).
3. Results
3.1. Micro-CT analysis of PCSD1-injected mouse
femurs revealed osteolytic and osteoblastic bone
lesion formation
Quantitative microstructural analysis was performed on the
femurs frommice directly injectedwith either PCSD1 cells or
Figure 1 2D micro-CT images of Control-injected (Matrigel alone) and PCSD1-injected Rag2/gc
/ mouse femurs and X-ray of
the PCSD1 xenograft donor patient’s femur pre- and post-hemi-arthroplasty. (A) Representative coronal 2D micro-CT of images from
five mice each of the Control group and the PCSD1 group. Mouse numbers M1eM5 for the Control group in which the right femur was
directly injected with Matrigel/media alone are shown (total number of mice in Control group, nZ 8). Mouse numbers M9eM13 are
shown for the PCSD1 group in which the right femur was injected with PCSD1 cells in Matrigel (total number of mice in PCSD1 group,
n Z 13). (B) X-ray of the PCSD1 xenograft donor patient’s femur pre- and post-hemi-arthroplasty. The numbers on the brackets
refer to the mouse identification numbers in our records and can be deleted from the figure.
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injection was confirmed by the presence of the injection hole
in the micro-CT scan of the femur condyle. Two dimensional
images of the femurs were compared between the Control
(n Z 8) and PCSD1 (n Z 13) groups (Fig. 1). Significant hy-
pertrophic changes and high bone density regions were seen
along the cortical bone in the PCSD1-injected right femurs
particularly on the lateral side compared to the Matrigel/
media-injected right femurs of the Control group (Fig. 1). In
contrast, most of the PCSD1-injected femurs showed low
bone density at the distal condyle, trabecular region and in
the proximal femur head. A minor sub-group of PCSD1 sam-
ples showed hypertrophic changes in the trabecular bone.
Fractures were also detected in some of the PCSD1 groups of
femurs as seen in Fig. 2 near the femur head. Bone reaction or
bone lesions were not seen in the un-injected, contra-lateral
(Fig. 2A and Supplemental Fig. 3A, B, C) femurs of either the
Control or PCSD1 group.
The donor patient’s X-rays pre- and post-right hip hem-
iarthroplasty are shown in Fig. 1B. An abnormal, perme-
ative pattern of bone destruction of the proximal femur
metadiaphysis was identified consistent with metastatic
disease (Fig. 1B). The lesion was approximately 10 cm in
length and occupied the entire width of the femur. There
was a subtle, undisplaced crack through the medial femoral
cortex just below the lesser trochanter consistent with anFigure 2 3D micro-CT images of PCSD1-injected condyle and w
femur (condyle), (B) the distal femur underside (condyle, undersi
osteolytic reaction and fracture at proximal femur head.undisplaced pathologic fracture. Subtle periosteal reaction
is present just inferior to the lower trochanter at the
fracture site. Abnormal sclerotic foci are seen. Pathology
showed metastatic prostatic adenocarcinoma. Thus, the
intra-femoral xenograft, PCSD1, of the patient’s bone
metastatic tumor cells replicated the osteolytic lesion at
the proximal femur including periosteal reaction and frac-
ture. In addition, the sclerotic features were consistent
with osteoblastic features in the PDX.
Structural changes were examined in 3D micro-CT images
of the injected femurs as shown in Fig. 2 and Supplemental
fig. 3. Osteolytic lesions were seen especially in the distal
condyle area and in the proximal area of the femur head
which had porous bone full of small cavities. In contrast, the
cortical bone along the length of the femur was broader and
showed irregular, jagged extensions especially on the lateral
side (Fig. 2 and Supplemental fig. 3) [24].
3.2. PCSD1 tumor cells were located within
osteolytic and osteoblastic bone lesions
In order to determine the location of PCSD1 tumor cells
relative to the bone microstructure features observed in
micro-CT analysis, H&E histochemical staining was per-
formed on sagittal sections of the legs from the samehole femur showing osteolytic bone reaction in (A) the distal
de) (C) osteoblastic reaction along lateral side of femur shaft
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showed that the femur condyle of the Control (Matrigel
plus media-only, Fig. 3A, left panel), contained bone
marrow cells (green arrows), while the endosteal space of
the femur condyle from the PCSD1-injected femur was
filled PCSD1 tumor cells (black arrow, Fig. 3A, right panel).
The tibia of both the Control and PCSD-1 injected mice
contained only bone marrow cells (green arrows). At
higher magnification the PCSD1 tumor cells (yellow arrow,
Fig. 3B, top right panel) were observed growing within the
femur directly adjacent to the bone (dark blue arrow).
PCSD1 tumor cells seen in Fig. 3B grew within the femur
endosteum and within the mixed osteolytic and osteo-
blastic lesions with periosteal bone reaction (medium blue
arrow) and also invaded the adjacent skeletal muscle
(light blue arrow). Comparison of H&E stained cortical
periosteal regions sagittal sections of PCSD1-injected fe-
murs showed tumor cells adjacent to regions of periosteal
reaction along femur shaft and osteoblastic bone forma-
tion (Supplemental fig. 4).
Masson’s trichrome staining was performed on femur
sections to visualize collagen and bone (blue), keratin andFigure 3 Histology of sagittal sections of PCSD1- compared to Con
the knee joints of Control (left panel) and PCSD1 (right panel) inje
images of sagittal sections of whole right leg. (B) Top panels: PCSD
Image of PCSD1 tumor cells (yellow arrows) within femur endoste
cancer cells (upper yellow arrow), dark blue arrow shows femur bo
panel shows 200 magnified image of muscle-invading PCSD1 tumo
red arrow shows femur condyle bone, dark blue shows bone, bla
images of serial sagittal sections of whole right leg. (C) Masson’s tric
lytic regions and osteoblasts in regions of rapid bone formation and
stained with Masson’s trichrome which stained keratin and muscle
pink), and cell nuclei (dark brown to black). Multi-nucleated oste
distal femur in an osteolytic lesion. (D) Hypertrophic region of new
with mixed osteolytic and osteoblastic bone reaction. Large, whit
cation surrounded by osteoblasts (green arrows).muscle fibers (red), cytoplasm (light red or pink), and cell
nuclei (dark brown to black). As shown in Fig. 3C the multi-
nucleated osteoclast cells (red arrow) were present in bone
resorption bays in the distal femur in an osteolytic lesion. In
Fig. 3D, a hypertrophic region of newly forming bone can be
seen in the proximal femur neck region. Ossifying endo-
chondral cells in the zone of cartilage calcification were
surrounded by osteoblasts (green arrow). Thus, within the
bone lesions there are PCSD1 tumor cells, osteoclasts in
lytic regions and osteoblasts in regions of rapid bone for-
mation and periosteal reaction.
3.3. Quantitative 2D micro-CT bone measures
showed osteolytic lesions were localized to distal
and proximal ends while osteoblastic lesions were
localized along the cortical bone
In order to corroborate the visual observations, tumor-
induced changes in bone structure were quantified
including: total femur length, BV at the distal and proximal
ends and along the shaft of the femur in micro-CT analysis.trol-injected mice. (A) Images of H&E stained sections through
cted mice at 200 magnification. Inset lower right shows H&E
1 cells within femur condyle adjacent to bone. Bottom panels:
um (lower yellow arrow) and muscle-invading PCSD1 prostate
ne, light blue arrow shows skeletal muscle fibers. Right, lower
r cells (yellow arrow). Green arrow shows bone marrow cells,
ck arrow shows PCSD1 prostate cancer cells. Inset shows H&E
hrome staining of femur sections showed osteoclasts present in
periosteal reaction. Sections of PCSD1-injected femur sections
fibers (red), collagen and bone (blue), cytoplasm (light red or
oclast cells (red arrow) present in bone resorption bays in the
ly forming bone can be seen in the proximal femur neck region
e cells are maturing cartilage cells in zone of cartilage calcifi-
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compared to the uninjected, left leg in both the Control
and PCSD1 groups. Interestingly, the right, injected femurs
were shorter than the left, uninjected femurs in both the
Control group and the PCSD1 group (Supplemental fig. 5).
The intra-femoral injections were performed in six to eight
week old mice which are still in the late stages of devel-
opment. This analysis revealed the negative influence on
bone growth of the injection through the growth plate in
the condyle of the femur. Therefore, importantly, the
comparisons of quantification of bone changes were per-
formed only between the injected, right femurs comparing
the effects of injecting the Control (media plus Matrigel
alone) to the injection of PCSD1 cells.
The cross-sectional BV was determined along the longi-
tudinal axis of the whole bone using the 2D micro-CT images
(Fig. 4). BV and TV were measured at four specific locations
along the length of the bone: condyle, trabecular bone,
cortex, and proximal bone as shown in Fig. 4A. Their loca-
tions along the length of the femur are shown in Fig. 4B.
The ratio of the mean cross-sectional BV/TV ratio along the
length of the femur is plotted in Fig. 4C. The BV/TV ratio
was lower in the spongy, porous bone at the condyle and
proximal ends of the femur and increased along the
cortical, dense bone in the shaft of the femurs in ControlFigure 4 Comparison of 2D micro-CT images between Control an
volume along length of the femur. Quantitation of bone volume in se
was calculated on 2D micro-CT images. (A) Axial cross-section mi
proximal femur of Control and PCSD1-injected femurs. Injection
Corresponding quantified regions along the longitudinal axis of sag
(mm3) in each region was plotted against relative position along femfemurs shown as the blue line in Fig. 4C. The changes in the
BV/TV ratios in PCSD1 femurs (red line) were the opposite
of those in the Control group. PCSD1 group had significantly
less BV expressed as lower BV/TV ratios at the ends of the
bone in the condyle and proximal femur than the Control
group. Conversely, the cortical bone area along the shaft of
the femur had significantly increased BV and BV/TV ratio in
the PCSD1 compared to the Control group. In trabecular
bone area (trabecular bone and cortical bone outside the
trabecular bone), the BV of PCSD1 group and Control group
were almost same. Therefore, the transition in BV along the
longitudinal axis showed decreased BV at the ends and
increased BV along the femur shaft of the PCSD1 group
compared to the Control group.
3.4. Distal condyle and proximal femur ends had
significantly lower BV in PCSD1-injected femurs in
3D micro-CT analysis
Analysis of BV in 3D micro-CT images was performed on the
condyles of PCSD1 and Control femurs. The condyle of the
femur forms part of the knee joint and consists of spongy
bone. BV/TV of the PCSD1 group was significantly less than
the Control group (47.31  8.32)% vs. (61.88  1.78)%,d PCSD1 groups showed reciprocal transitional changes in bone
rial cross-sections along the longitudinal axis of the whole bone
cro-CT images through condyle, trabecular region, cortex and
site needle holes can be seen in condyle cross-sections. (B)
ittal 2D micro-CT sections of the right femur. (C) Bone volume
ur length (expressed as relative length segmental image slices).
Figure 5 3D Micro-CT analysis revealed decreased bone vol-
ume (BV) at the end of femur in the condyle but increased BV,
porosity and bone shaft diameter in cortical bone in PCSD1-
injected femurs compared to Control-injected femurs. (A)
Analysis of BV in 3D micro-CT images was performed on the
condyles of PCSD1 and Control femurs. The condyle of the femur
forms part of the knee joint and consists of spongy bone. BV and
BV/TV of the PCSD1 group was significantly less than the Control
group. Consistent with this, the ratio of bone space to bone
volume (BS/BV) of the PCSD1 group was significantly more than
the Control group. (B) Cortical bone along femur shaft had higher
BV and porosity in PCSD1-injected femurs than Control-injected
femurs. PCSD1 group had significantly more BV than Control
group in cortical bone area, whereas BV/TV in PCSD1 group was
236 T. Hirata et al.p<0.01). Consistent with this, the BS/BV ratio of the PCSD1
group was significantly more than the Control group
(Fig. 5A).
The proximal end of the femur forms part of the hip joint
and also consists of spongy bone. Like the condyle, the BV/
TV of the proximal femur of the PCSD1 group was signifi-
cantly less than the Control group (40.97  9.04)% vs.
(55.45  2.37)%, p<0.01). Likewise, the BS/BV ratio of the
PCSD1 group was significantly more than the Control group
(Supplemental fig. 6).
3.5. Cortical bone had significantly increased BV,
porosity and maximum diameter of the femur bone
shaft in PCSD1-injected femurs
The PCSD1 group had significantly higher BV in the cortical
bone area than the Control group (Fig. 5B, 2.03  0.44 vs.
1.73  0.15 mm3, p Z 0.036) which was consistent with
qualitative observations of 2D and 3D images (Figs. 1 and 2).
Unexpectedly, the ratio of BV/TV in PCSD1 group was
slightly lower than the Control groups (98.95  1.14)% vs.
(99.84  0.30)%, p Z 0.01). While the maximum diameter
of the bone shaft in PCSD1 group was larger than Control
group (Fig. 5B), the mean Cs. Th which takes into account
the density as well as overall volume of the bone showed no
significant difference between two groups. This apparent
discrepancy was revealed to be due to increased porosity of
the cortical bone of the PCSD1 group. The ratio of BS/BV,
Po(op) and Po(tot) which indicate irregularity of the bone
group was significantly increased in PCSD1 group than
Control group (Fig. 5B).
Many samples in the PCSD1 group showed greater hy-
pertrophic, osteoblastic changes on the lateral side of the
bone shaft as seen in 2D and 3D micro-CT images (Figs. 1
and 2, Supplemental Fig. 3). The maximum diameter of
the bone shaft at the third trochanter was measured to
quantify these changes. The maximum diameter of the
right bone shaft at the third trochanter in PCSD1 group was
significantly larger than of the left, uninjected femur,
whereas there was no significant difference in Control
group between the right and left third trochanters
(Fig. 5C).
3.6. Trabecular bone was a transitional zone
Overall the PCSD1 group showed no significant differences
among the bone quantity parameters in the trabecular bonelower than Control group. The maximum diameter of the bone
shaft in PCSD1 groupwas longer than Control group, however, the
mean thickness of the bone shaft (Cs. Th) showed no significant
difference between two groups. BS/BV, open porosity (Po(op))
and total porosity (Po(tot)) which indicate irregularity of the
bone group showed greater ratio in PCSD1 group than Control
group. (C) PCSD1 tumor growth increased themaximumdiameter
of the femur bone shaft. The maximum diameter of the bone
shaft was measured to quantify these changes. The maximum
diameter of the right bone shaft in PCSD1 group showed signifi-
cantly larger diameter than left femur, whereas there was no
significant difference in Control group.
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(Tb.Th) (Supplemental Table 1). BV and BS/BV in PCSD1
group were higher than Control group and the PCSD1 group
had thinner trabeculae (Tb.th) than the Control group.
While there was no significant difference in the BV/TV ratio
between PCSD1 group and Control group, there was wide
range of deviation within the PCSD1 group.
To further characterize the variability of the trabecular
bone in the PCSD1 group, the PCSD1 group was divided into
two sub-groups: the high BV/TV group (nZ 7) and low BV/TV
group (nZ 6) (Supplemental Fig. 7). All parameters were re-
evaluated and compared among these three sub-groups. In
this analysis, these three groups showed significant differ-
ence in almost all parameters except for trabecular sepa-
ration (Tb.Sp). Thus, trabecular bone demonstrated a more
complex combination of changes in BV, trabecular structure
and porosity indicating that it seems to be a transitional zone
between spongy and cortical bone such that the net effect of
PCSD1 tumor growth on the trabecular bone can tilt in either
direction and perhaps may be affected by factors such as the
exact location of injection within the endosteal space,
tumor cell deposition site, initial tumor growth site and
tumor size.4. Discussion
Different types of bone lesions typically occur within an
individual prostate cancer patient, however, the mechanism
that determines why a specific type of bone lesion forms is
not understood [6]. In this study we performed quantitative
2D and 3D micro-CT analysis of bone lesions in our new PDX
model of bone metastatic prostate cancer, PCSD1. PCSD1
formed osteolytic, osteoblastic and mixed bone lesions
when directly injected into the endosteal space in the
femur of Rag2/gc
/ male mice that were similar to those
seen in the donor patient. We noticed that the osteolytic
bone lesions appeared to be restricted to the distal and
proximal ends of the femur while the osteoblastic lesions
consistently formed along the femur shaft in the cortical
bone. Quantitative analyses of bone microstructures
corroborated these qualitative observations and established
that the BV was significantly lower at the ends of the PCSD1
tumor cell-injected femurs and aberrantly high along the
lateral side of the femur shaft compared to controls.
Intriguingly, bone reactions in the trabecular bone region
which connects the ends of the bone to the cortical bone
were mixed but could be sub-divided into primarily osteo-
lytic or osteoblastic in nature, and thus, may reflect a
transition zone between different bone microenvironments.
This is the first report of reproducible, regional localization
of bone microenvironment-specific differences in the types
of prostate cancer-induced bone lesions in any PDX model.
The reproducible regional specificity of the types of
bone lesions that formed in our PCSD1 model leads us to
hypothesize that the PCSD1 cells interact with bone-niche
and bone region-specific cell types that regulate osteolytic
versus osteoblastic bone responses. Osteolytic bone
response may be due to preferential activation of osteo-
clasts in the spongy bone at the ends of the femur and/or
inhibition of osteoblasts and their bone forming functions in
response to PCSD1 cells. Conversely, the osteoblasticresponse in the long bone region of the femur shaft may be
due to increased osteoblast activation. However, a strong
periosteal reaction indicative of rapid tumor growth in
concert with increased bone porosity was also seen in these
regions. This may indicate that an osteolytic reaction pre-
cedes and/or coincides with osteoblastic bone growth as
has been previously described in other xenograft models
and in studies of bone turnover markers in patients with
bone metastatic prostate cancer [3,11]. The time depen-
dence of the bone lesion formation and consequent BV
differences in the proximal, distal and cortical regions of
the bone will now be investigated at earlier time points in
the PCSD1 model to further investigate the possible
coupling of osteoblastic response following initial
osteoclastogenesis.
Interestingly, the intermediate region of trabecular
bone showed mixed lesions that could be sub-classified as
predominantly osteolytic or osteoblastic. This fits with the
model that the relationship between location and the type
of bone lesion formed may be a gradient rather than a
distinct border and that the trabecular bone is a transi-
tional zone.
Regional localization of different cells within the bone
marrow has been shown to support different functional
capacities of human hematopoietic stem cells in bone
marrow biopsies and xenograft models [25]. Guezguez and
coworkers [25] showed that hematopoietic stem cells
(HSCs: CD45RACD34þCD38) from human bone marrow
biopsies that had full self-renewal and multi-lineage po-
tential were preferentially isolated from the trabecular
bone area in the ends of the femur compared to the long
bone area or shaft. The full HSC function was attributed to
their location in the trabecular bone area where they
physically associated with osteoblasts and mesenchymal
stem cells in rather than being solely a cell autonomous
property. Therefore, this work showed that anatomical
regions within the bone and bone marrow dictated the
function and heterogeneity of HSC cells. The specific
interaction of HSCs with specialized cells within the
different bone niches regulated HSC function via a non-cell
autonomous mechanism [25].
In cancer, bone niche-dependent localization has been
shown to regulate response to therapy. Goff and coworkers
[26] demonstrated that quiescent, therapy-resistant leu-
kemia stem cells were located at the endosteum. In this
study, chronic myelogenous leukemia stem cells (CML-SCs)
were purified from bone marrow of CML patients in blast
crisis (BC-LSCs) who were resistant to the standard-of-care
tyrosine kinase inhibitor (TKI), dasatinib. The cells were
transplanted into Rag2/gc
/ mice where they showed
resistance to same therapy but only if they were located in
the bone marrow. The resistant BC-LSCs were preferen-
tially located in the endosteum. Therefore, spatial location
of normal hematopoietic stem cells and cancer stem cells in
the bone marrow have been shown to regulate their sur-
vival and functional regenerative capacities as well as their
sensitivity to targeted therapeutic agents [26].
Prostate cancer bone metastases often become resistant
to standard therapies including androgen deprivation, ra-
diation and chemotherapy. Despite the overall survival and
bone benefits shown in the AFFIRM and PREVAIL trials the
majority of these enzalutamide-treated advanced prostate
238 T. Hirata et al.cancer patients still progressed and died of bone metastatic
prostate cancer [18]. New bone metastasis therapies are
targeted against osteolytic lesions such as denosumab,
anti-RANKL, and TGFbetaRII inhibitor [27e29]. However,
the osseous lesions at prostate cancer bone metastatic sites
in prostate cancer are predominantly osteoblastic types of
differ from other cancers such as breast cancer bone me-
tastases which are typically purely osteolytic. Thus, these
therapies are effective in reducing the osteolytic compo-
nent in prostate bone metastatic lesions but there is no
current treatment for osteoblastic lesions [18]. A model in
which bone lesions are reproducibly induced in the
different bone regions would be invaluable for measuring
the effects of different therapies on the type of bone le-
sions that arise from the interaction of tumor cell and
different bone microenvironments. Our PCSD1 model with
reproducible bone lesion formation and bone-region spe-
cific types of bone lesions allows for a systematic, quanti-
tative investigation of the mechanisms and the effects of
current therapies such as the anti-androgen, enzalutamide
alone or in combination with novel therapies. We showed
that PCSD1 tumor cells were resistant to anti-androgen
therapy specifically in the bone-niche [30]. Therefore, the
PCSD1 intra-femoral xenograft model can be used to
determine quantitatively the effects of current treatments
such as enzalutamide and/or docetaxel on survival of
prostate cancer cells in the spongy versus cortical bone-
niches and determine which of these niches may perhaps
preferentially support prostate cancer stem cells or
castrate-resistant prostate cancer cells [30].
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